Moreover, our pharmacologic results suggest that targeting the upstream AMPK/CAMKK complex may offer therapeutic benefit to KRAS/LKB1 mutant lung adenocarcinoma patients. The gene discussed is KRAS; the disease is lung adenocarcinoma.